How does A382150's PB Ratio compare to its peers?

A382150 is expensive based on its Price-To-Book Ratio (6x) compared to the peer average (1.5x).

How does A382150's PB Ratio compare vs other companies in the KR Pharmaceuticals Industry?

A382150 is expensive based on its Price-To-Book Ratio (6x) compared to the KR Pharmaceuticals industry average (1.1x).

What is A382150's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate A382150's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of A382150 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate A382150's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

A382150 Stock Overview

Develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. More details

A382150 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (₩436M)

Does not have a meaningful market cap (₩75B)

My Notes

Capture your thoughts, links and company narrative

Oncocross Co., Ltd. Competitors

Enzychem Lifesciences

KOSDAQ:A183490

₩118.6b

GL Pharm Tech

KOSDAQ:A204840

₩75.8b

WITHUS PHARMACEUTICALLTD

KOSDAQ:A330350

₩92.8b

Ahn-Gook Pharmaceutical

KOSDAQ:A001540

₩74.6b

Price History & Performance

Summary of share price highs, lows and changes for Oncocross
Historical stock prices
Current Share Price	₩6,330.00
52 Week High	₩14,450.00
52 Week Low	₩6,260.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-29.35%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A382150	KR Pharmaceuticals	KR Market
7D	-12.3%	1.4%	-0.8%
1Y	n/a	-0.07%	-10.1%

Return vs Industry: Insufficient data to determine how A382150 performed against the KR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how A382150 performed against the KR Market.

Price Volatility

Is A382150's price volatile compared to industry and market?
A382150 volatility
A382150 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.4%

Stable Share Price: A382150's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A382150's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	31	Yi Rang Kim	www.oncocross.com

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases.

Oncocross Co., Ltd. Fundamentals Summary

How do Oncocross's earnings and revenue compare to its market cap?
A382150 fundamental statistics
Market cap	₩75.06b
Earnings (TTM)	-₩5.83b
Revenue (TTM)	₩435.70m

172.3x

P/S Ratio

-12.9x

P/E Ratio

Is A382150 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A382150 income statement (TTM)
Revenue	₩435.70m
Cost of Revenue	₩207.88m
Gross Profit	₩227.82m
Other Expenses	₩6.06b
Earnings	-₩5.83b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-491.71
Gross Margin	52.29%
Net Profit Margin	-1,338.22%
Debt/Equity Ratio	0%

How did A382150 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 01:24
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncocross Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution